Halozyme Therapeutics, Inc. HALO
We take great care to ensure that the data presented and summarized in this overview for HALOZYME THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HALO
View all-
Black Rock Inc. New York, NY18.2MShares$786 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$562 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$279 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.12MShares$177 Million3.73% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.79MShares$163 Million0.24% of portfolio
-
Alliancebernstein L.P. New York, NY3.67MShares$158 Million0.05% of portfolio
-
Jpmorgan Chase & CO New York, NY3.24MShares$140 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.03MShares$130 Million0.01% of portfolio
-
Macquarie Group LTD Australia, C32.99MShares$129 Million0.14% of portfolio
-
Td Asset Management Inc2.54MShares$109 Million0.1% of portfolio
Latest Institutional Activity in HALO
Top Purchases
Top Sells
About HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Transactions at HALO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 22
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-5.61%
|
$450,000
$45.38 P/Share
|
May 22
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.31%
|
$80,000
$8.11 P/Share
|
May 21
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-5.61%
|
$450,000
$45.16 P/Share
|
May 21
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.31%
|
$80,000
$8.11 P/Share
|
Apr 25
2024
|
Matthew L. Posard |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+5.15%
|
-
|
Apr 25
2024
|
Connie Matsui |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+3.25%
|
-
|
Apr 25
2024
|
Akiko Moni Miyashita |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+23.84%
|
-
|
Apr 25
2024
|
Mahesh Krishnan |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+50.0%
|
-
|
Apr 25
2024
|
Jeffrey William Henderson |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+10.81%
|
-
|
Apr 25
2024
|
Bernadette Connaughton |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+12.2%
|
-
|
Apr 25
2024
|
Barbara Gayle Duncan |
BUY
Grant, award, or other acquisition
|
Direct |
6,501
+29.21%
|
-
|
Apr 17
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-5.61%
|
$380,000
$38.49 P/Share
|
Apr 17
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.31%
|
$80,000
$8.11 P/Share
|
Apr 16
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-5.61%
|
$380,000
$38.35 P/Share
|
Apr 16
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.31%
|
$80,000
$8.11 P/Share
|
Mar 26
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,618
+2.24%
|
$139,416
$12.32 P/Share
|
Mar 13
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-6.0%
|
$420,000
$42.27 P/Share
|
Mar 13
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.95%
|
$100,000
$10.09 P/Share
|
Mar 12
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-6.0%
|
$410,000
$41.64 P/Share
|
Mar 12
2024
|
Michael J. La Barre SVP, CHIEF TECHNICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.66%
|
$120,000
$12.07 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 86.8K shares |
---|---|
Exercise of conversion of derivative security | 420K shares |
Open market or private sale | 300K shares |
---|---|
Payment of exercise price or tax liability | 88.5K shares |